News | Stents Bifurcation | May 29, 2018

Medtronic Begins Bifurcation Cohort of U.S. RESOLUTE ONYX Study

Multi-center trial will evaluate drug-eluting stents as treatment option for bifurcation lesions in patients with coronary artery disease

Medtronic Begins Bifurcation Cohort of U.S. RESOLUTE ONYX Study

May 29, 2018 – Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions. Bifurcation lesions account for approximately 20 percent of all percutaneous coronary interventions (PCI).[i] The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx DES in sizes ranging from 2–5 mm in diameter.

The Resolute Onyx DES is not approved for the treatment of bifurcation lesions in the U.S.

Bifurcation lesions occur when plaque builds up around the junction of two coronary arteries – where one branches off another. These lesions are considered challenging to treat because of anatomical variations in the vessels and the difficulty associated with reaching the side branches. Treatment of bifurcation lesions are commonly associated with lower success rates and increased rates of long-term adverse cardiac events.1

“Patients with bifurcation lesions present a unique challenge for interventional cardiologists. This study will help us evaluate these patients in a controlled setting, which will help expand our knowledge base,” said Matthew J. Price, M.D., interventional cardiologist at Scripps Clinic in La Jolla, Calif., and national principal investigator of the Bifurcation Cohort of the RESOLUTE ONYX Post-Approval Study. “The unique design of Resolute Onyx DES may be well-suited to treat bifurcation lesions in a wide range of vessel sizes.”

The Resolute Onyx DES platform features Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST). CST is a unique Medtronic method of stent manufacturing, which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. Core Wire Technology enables thinner struts while maintaining structural strength and visibility.

The multi-center, single-arm study intends to enroll 250 patients with bifurcation lesions from 30 sites in the United States and Europe. The primary endpoint is target vessel failure (TVF) at 12 months. Study participants will be followed for three years and receive regular follow-up health assessments. Data from the study will be used to support an application for an indication expansion to include bifurcation lesions for the Resolute Onyx DES from the U.S. Food and Drug Administration (FDA).

The Resolute Onyx DES received CE Mark in September 2014 and FDA approval in April 2017. The device is currently indicated in the United States for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 35 mm in native coronary arteries, with reference vessel diameters of 2-5 mm.

For more information: www.medtronic.com


Related Content

News | Stents Bifurcation

September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the ...

Home September 21, 2022
Home
News | Stents Bifurcation

January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care facility, announces the first ...

Home January 18, 2018
Home
Videos | Stents Bifurcation

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...

Home November 15, 2017
Home
News | Stents Bifurcation

November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion ...

Home November 01, 2017
Home
News | Stents Bifurcation

September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was ...

Home September 21, 2017
Home
News | Stents Bifurcation

March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch ...

Home March 31, 2017
Home
Videos | Stents Bifurcation

This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent. It became the first ...

Home March 06, 2017
Home
Technology | Stents Bifurcation

March 6, 2017 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for the Tryton Side ...

Home March 06, 2017
Home
News | Stents Bifurcation

October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and ...

Home October 28, 2016
Home
News | Stents Bifurcation

October 14, 2015 — Tryton Medical Inc. announced results from the pivotal Tryton Confirmatory Study confirming the ...

Home October 14, 2015
Home
Subscribe Now